Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 151Leukemia 67Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Leukemia, Myelomonocytic, Acute 26Leukemia, Monocytic, Acute 26Myelodysplastic Syndromes 24Leukemia, Erythroblastic, Acute 23Leukemia, Megakaryoblastic, Acute 22Congenital Abnormalities 21Leukemia, Promyelocytic, Acute 13Leukemia, Myelomonocytic, Chronic 12Anemia, Refractory, with Excess of Blasts 12Recurrence 8Myeloproliferative Disorders 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Lymphoma 7Leukemia, Myeloid, Chronic-Phase 7Leukemia, Eosinophilic, Acute 7Leukemia, Biphenotypic, Acute 7Carcinoma, Hepatocellular 7Leukemia, Basophilic, Acute 6Blast Crisis 6Neoplasm, Residual 4Multiple Myeloma 4Lymphoma, Non-Hodgkin 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma, Follicular 4Neutropenia 3Neoplasms, Plasma Cell 3Lymphoma, Large-Cell, Immunoblastic 3

Interventions

Cyclophosphamide 9Pemetrexed 6pembrolizumab 5fludarabine 5Gemcitabine 5Cisplatin 5Carboplatin 5ponatinib 4atezolizumab 4Rituximab 4Dexamethasone 4Bevacizumab 4130-nm albumin-bound paclitaxel 4Sunitinib 3Melphalan 3Lutetium 3Doxorubicin 3Bortezomib 3tetulomab tetraxetan lu-177 2pralsetinib 2pomalidomide 2osimertinib 2napabucasin 2isatuximab 2fludarabine phosphate 2ficlatuzumab 2entrectinib 2entinostat 2durvalumab 2cobimetinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms by Histologic Type × Idarubicin × Clear all
NCT06001788 2026-04-14

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Kura Oncology, Inc.

Phase 1 Recruiting
171 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Leukemia, Myeloid, Acute, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡